Journal
DIABETES OBESITY & METABOLISM
Volume 25, Issue -, Pages 3-20Publisher
WILEY
DOI: 10.1111/dom.15059
Keywords
CSII; cost-effectiveness; glycaemic control; insulin pump therapy
Categories
Ask authors/readers for more resources
The global prevalence and increasing incidence rates of type 2 diabetes (T2D) have significant impacts on healthcare costs and quality of life. However, the use of continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is underutilized in T2D management despite technological advances. This review examines the literature on CSII use in T2D patients, discusses potential benefits for specific patient groups, identifies challenges associated with CSII use, and proposes future research directions to expand its applicability to a broader T2D population.
The global prevalence and increasing incidence rates of type 2 diabetes (T2D) have rippling effects on healthcare costs and diminishing quality of life. Despite advances in technology, continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is rarely being recommended by healthcare professionals and is underutilized in T2D management. This review analyses the available literature on CSII use in T2D patients. In addition, it discusses which groups of patients may benefit from CSII, identifies potential challenges associated with CSII use, and suggests future directions for research to expand the applicability of this technology to the broader T2D population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available